AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23024014
Drug: Weekly alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly alcohol intake (10 units/week increase)
Trial: 18477075
Drug: Fluid resuscitation
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid resuscitation guided by hourly urine output (HUO Group, n=12)
Trial: 15909462
Drug: Vaginal ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring with low dose progesterone (1.8 g)
Trial: 15909462
Drug: Vaginal ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring with high dose progesterone (3.6 g)
Trial: 15909462
Drug: Vaginal ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring (both doses)
Trial: 10594396
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg o.d.)
Trial: 10594396
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg o.d.) and Ranitidine (300 mg b.d.)
Trial: 1719288
Drug: Oral bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisoprolol (20 mg) at rest
Trial: 1719288
Drug: Oral bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisoprolol (20 mg) with iterative stress tests
Trial: 84441
Drug: DTIC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC alone or in combination with other cytotoxic agents (Oncovin, Bleomycin, Adriblastin)
Trial: 31173898
Drug: Decidua stromal
RxNorm normalized name: Larix decidua resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decidua stromal cells (DSCs) infused at a median dose of 1.2 (range, 0.9 to 2.9) × 10^6 cells/kg body weight, median of 2 doses given 1 week apart.
Trial: 24517061
Drug: Warming Shen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming Shen, enhancing Yang, invigorating qi, and nourishing blood method (WSEYIQNBM) combined artificial cycle therapy
Trial: 24517061
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine artificial cycle therapy
Trial: 18064333
Drug: G-CSF-mobilized peripheral
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF-mobilized peripheral blood mononuclear cells (M-PBMNC)
Trial: 7917743
Drug: Sevoflurane anaesthesia
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane anaesthesia (mean dose 10.6 MAC-h)
Trial: 7917743
Drug: Isoflurane anaesthesia
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane anaesthesia (mean dose 8.5 MAC-h)
Trial: 17443125
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg nicotine via nasal spray
Trial: 17443125
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine via nasal spray
Trial: 17443125
Drug: Nicotine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (any dose)
Trial: 17274039
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) 2 or 3 mg daily for 30 weeks
Trial: 17274039
Drug: Levodopa 200
RxNorm normalized name: levodopa 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 200 or 300 mg daily for 30 weeks
Trial: 15492340
Drug: Nurse care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse care management (structured telephone surveillance and treatment for heart failure, coordination with primary care physicians)
Trial: 8160609
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet and daily physical exercise
Trial: 3042053
Drug: CMF +
RxNorm normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF + tamoxifen (30 mg per day during 2 years)
Trial: 3042053
Drug: CMF (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (chemotherapy alone)
Trial: 27124254
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care control treatment (including brief peer coaching and brief nurse counseling)
Trial: 24408892
Drug: PEERS(®) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEERS(®) treatment group (TG)
Trial: 17403126
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and twice daily biphasic 30/70 human insulin mixture (n = 27)
Trial: 17403126
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and bedtime NPH insulin (n = 26)
Trial: 17403126
Drug: Metformin, bedtime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, bedtime NPH insulin and mealtime repaglinide (n = 25)
Trial: 15871642
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg intravenously (n=37)
Trial: 15871642
Drug: prochlorperazine 10
RxNorm normalized name: prochlorperazine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prochlorperazine 10 mg intramuscularly (n=41)
Trial: 12851985
Drug: Anti-TNF-alpha immunobiologics
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-alpha immunobiologics (e.g. etanercept, infliximab)
Trial: 12851985
Drug: Apoptosis-inducing treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apoptosis-inducing treatments
Trial: 26272720
Drug: Ephedrine 10
RxNorm normalized name: pseudoephedrine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 10 mg iv at the time of CSE
Trial: 14612479
Drug: Antidepressant medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medications and/or 6 to 8 sessions of psychotherapy (Problem‐Solving Treatment in Primary Care)
Trial: 11177604
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of isolated disseminated tumor cells in bone marrow (IDTBM) using monoclonal antibody A 45‐B/B3
Trial: 1431257
Drug: M15 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M15 (15 mg/kg)
Trial: 1431257
Drug: M25 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M25 (25 mg/kg)
Trial: 3881630
Drug: Intratumoral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral immunotherapy with Corynebacterium parvum followed 2 weeks later by surgery and postoperative C parvum for 2 years
Trial: 22816878
Drug: Budesonide/formoterol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART™, Turbuhaler®) 160/4.5 μg twice daily plus as needed
Trial: 22816878
Drug: Conventional fixed-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fixed-dose treatment (ICS/LABA plus SABA or formoterol)
Trial: 10836651
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg for five doses given every 2 weeks)
Trial: 10836651
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mycophenolate mofetil, prednisone, and a calcineurin inhibitor)
Trial: 6392050
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg molsidomine sustained-release
Trial: 31304887
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual group
Trial: 29456191
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg azithromycin (low-dose)
Trial: 29456191
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg azithromycin (standard-dose)
Trial: 29456191
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (20 mg/kg and 30 mg/kg azithromycin)
Trial: 16383068
Drug: 50 mg/100
RxNorm normalized name: Janumet 50 mg/1000 mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/100 ml alcohol
Trial: 16383068
Drug: 80 mg/100
RxNorm normalized name: gentamicin 80 mg/100 mL-0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/100 ml alcohol
Trial: 8737213
Drug: Fat-rich meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-rich meal (600 ml, approximately 4000 kJ)
Trial: 8737213
Drug: Carbohydrate-rich meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich meal (600 ml, approximately 4000 kJ)
Trial: 8737213
Drug: Balanced meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced meal (600 ml, approximately 4000 kJ)
Trial: 8737213
Drug: Water (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (600 ml)
Trial: 1412115
Drug: Resistance breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance breathing training using a resistive breathing device (PFLEX) for 10 minutes five times daily with progressively larger resistances.
Trial: 3895960
Drug: Single-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose treatment with 500 mg clotrimazole
Trial: 3895960
Drug: 6-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-day treatment with 100 mg clotrimazole
Trial: 26372481
Drug: Doravirine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 25 mg
Trial: 26372481
Drug: Doravirine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 200 mg
Trial: 20152065
Drug: Individual CBT
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual CBT treatment
Trial: 16288704
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg/d orally for 1 month)
Trial: 12126818
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation combined with immediate androgen suppression (Goserelin 3.6 mg subcutaneously every 4 weeks for 3 years, and Cyproterone acetate 150 mg orally for 1 month starting 1 week before goserelin)
Trial: 7487847
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) without explicit exposure instructions
Trial: 7487847
Drug: Exposure and
RxNorm normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure and response prevention treatment without cognitive restructuring procedures
Trial: 2154431
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2 to 5)
Trial: 2154431
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg qid for ten days)
Trial: 19240996
Drug: NHT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHT and adjuvant hormonal therapy (HT)
Trial: 11172836
Drug: Progesterone 600
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone 600 mg/d for 3 weeks after a positive hCG result (Control)
Trial: 3202502
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline (A)
Trial: 28325148
Drug: M2000 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2000 (500 mg twice daily for 12 weeks)
Trial: 28325148
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no M2000 treatment)
Trial: 26122282
Drug: TDEE(DLW) (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDEE(DLW) (total daily energy expenditure assessed by doubly labeled water)
Trial: 18828814
Drug: Non-submerged implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-submerged implants (ITI)
Trial: 18828814
Drug: Submerged implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submerged implants (3i)
Trial: 16573704
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg once daily via Turbuhaler
Trial: 16573704
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily via Turbuhaler
Trial: 6396969
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg piridoxilate
Trial: 6396969
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg piridoxilate (with traffic noise)
Trial: 31985066
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + adjunct probiotic therapy (PT) in non-chewers (group 4)
Trial: 31985066
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + adjunct probiotic therapy (PT) in shamma users (group 2)
Trial: 22399084
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (not specified dosage)
Trial: 12514150
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg x kg(‐1) tramadol
Trial: 12514150
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg x kg(‐1) tramadol
Trial: 12514150
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg x kg(‐1) tramadol
Trial: 12514150
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg x kg(‐1) tramadol
Trial: 8544795
Drug: Regimen DD-RT
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen DD-RT (Vincristine + Actinomycin D + Cyclophosphamide + Whole Lung Radiation Therapy)
Trial: 8544795
Drug: Regimen J
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen J (Vincristine + Actinomycin D + Doxorubicin + Whole Lung Radiation Therapy)
Trial: 1830551
Drug: Quinapril (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10, 20, or 40 mg day‐1)
Trial: 28102978
Drug: Antipsychotic-naive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic-naive patients
Trial: 26138109
Drug: Ventral onlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventral onlay buccal mucosal graft urethroplasty
Trial: 9403542
Drug: A‐CVC (antibiotic-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐CVC (antibiotic- and antiseptic-coated central venous catheter)
Trial: 8218755
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg cisapride b.d.
Trial: 31674134
Drug: 0.5-mg intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg intravitreal ranibizumab injection
Trial: 31674134
Drug: Subconjunctival saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival saline injection (placebo)
Trial: 27965209
Drug: Chlorthalidone/amiloride combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone/amiloride combination pill
Trial: 16870915
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical management and once-weekly medication dispensing
Trial: 16870915
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical management and thrice-weekly medication dispensing
Trial: 16870915
Drug: Enhanced medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced medical management and thrice-weekly medication dispensing
Trial: 14566214
Drug: Transdermal buspirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal buspirone patches
Trial: 8769938
Drug: GTPN (TPN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTPN (TPN containing 0.23 g glutamine/kg.day)
Trial: 1430300
Drug: diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem SR 120 mg
Trial: 1430300
Drug: diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem SR 240 mg
Trial: 1430300
Drug: diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem SR 360 mg
Trial: 1430300
Drug: diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem SR 480 mg
Trial: 3950055
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg triazolam tablet in the morning (7 AM)
Trial: 3950055
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg triazolam tablet in the evening (10 PM)
Trial: 30698839
Drug: Prazosin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (16 mg)
Trial: 19912243
Drug: MMI 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI 30 mg
Trial: 19912243
Drug: MMI 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI 30 mg + KI
Trial: 19912243
Drug: MMI 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI 15 mg
Trial: 19912243
Drug: MMI 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI 15 mg + KI
Trial: 17879223
Drug: email bulimia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: email bulimia therapy (eBT)
Trial: 17012875
Drug: rDEN1Delta30 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rDEN1Delta30 vaccine (10^3 pfu)
Trial: 14616413
Drug: Voriconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (200 mg twice daily)
Trial: 8741449
Drug: Infusion cardioplegia
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion cardioplegia with recirculation type circuit
Trial: 31912285
Drug: Epiduroscopy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epiduroscopy with mechanical lysis of adhesions and medication (methylprednisolone and hyaluronidase)
Trial: 28883722
Drug: Aclidinium/formoterol (AB/FF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium/formoterol (AB/FF) 400/12 μg twice daily
Trial: 23881929
Drug: Pazopanib (VEGF-targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (VEGF-targeted agent)
Trial: 21241468
Drug: Topical ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical ranibizumab (Lucentis®) eye drops (2 mg/ml) four times daily for 1 month
Trial: 17163260
Drug: Lornoxicam 24
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 24 mg on day 1 followed by 8 mg twice daily for 5 days
Trial: 17163260
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 150 mg on day 1 followed by 50 mg twice daily for 5 days
Trial: 12574810
Drug: Calculated-dose strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated-dose strategy (based on regression formula)
Trial: 12574810
Drug: Standard-dose strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose strategy (fixed at 5 mg)
Trial: 9109105
Drug: Somatostatin (SRIF-14)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SRIF-14) 50 micrograms administered every hour between 2200 and 0100 hours
Trial: 3935298
Drug: Incremental doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental doses of nalbuphine administered approximately four hours after cardiopulmonary bypass
Trial: 3935298
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered approximately four hours after cardiopulmonary bypass
Trial: 29441995
Drug: S‐1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 plus oxaliplatin (SOX) as perioperative chemotherapy (group A, 50 patients)
Trial: 29441995
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (group B, 52 patients)
Trial: 23164226
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei Shirota 3 times daily for 12 weeks
Trial: 23164226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with standard medical therapy
Trial: 12744878
Drug: PFP-3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFP-3 vaccine
Trial: 10586395
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg once daily for 9 days